New drugs added to Medicare Part B step therapy program

For dates of service on or after July 1, 2023, the following drugs will be added to the Medicare Part B step therapy program. In-scope indications include all medically accepted indications unless otherwise noted in the table below. These step therapy requirements apply to commercial lines of business as well as Medicare.

The Centers for Medicare and Medicaid Services (CMS) previously issued guidance that provides Medicare Advantage plans the option of applying step therapy for physician-administered Part B drugs in a way that lowers costs and improves the quality of care for Medicare beneficiaries.

Security Health Plan first implemented step therapy requirements on May 1, 2019 and has added to the program periodically for new starts of certain targeted drugs.

Requested Product	Preferred Alternative Agent(s)	Special Comments
Vegzelma (Q5129)	Mvasi (Q5107), Zirabev (Q5118)	N/A
Vivimusta (J9999) Bendamustine (J9999)	Belrapzo (J9036), Bendeka (J9034)	Step therapy requirements DO NOT APPLY to the following FDA-approved indications: • Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within 6 months of treatment with rituximab or a rituximab-containing regimen.

Implementation will continue to be for new starts only (no use in the previous 365 days), meaning no beneficiaries currently receiving eligible step therapy drugs under Part B will have to change their drug. Step therapy prior authorization will be managed through Security Health Plan's specialty pharmacy medication partner, Magellan.
Please call 1-800-424-8243 or access their website at www.mrxgateway.com.